Novocure Ltd. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Novocure Ltd. is a global oncology company developing and commercializing Tumor Treating Fields (TTFields) therapy. The company markets three primary devices: Optune Gio (glioblastoma), Optune Lua (non-small cell lung cancer and malignant pleural mesothelioma), and Optune Pax (locally advanced pancreatic cancer). The company operates as a single reporting segment with headquarters in Switzerland and significant operations in the U.S., Israel, and Europe.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Net Revenues | $655.4 | $605.2 | +8% |
| Gross Profit | $488.5 | $468.0 | +4% |
| Gross Margin | 75% | 77% | -200 bps |
| Operating Loss | $(153.8) | $(170.5) | Improved |
| Net Loss | $(136.2) | $(168.6) | Improved |
| Diluted EPS | $(1.22) | $(1.56) | Improved |
| Cash & Short-Term Investments | $447.7 | $959.9 | Significant Decrease |
| Total Debt (Senior Secured Facility) | $200.0 | $100.0 | Increased |
Liquidity: As of December 31, 2025, the company held $93.5 million in cash and cash equivalents and $354.1 million in short-term investments. The decrease in total liquidity compared to 2024 was primarily due to the repayment of $560.9 million in convertible notes at maturity, partially offset by $100 million in new borrowings under the Tranche B Loan of the senior secured credit facility.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by $50.1 million (8%), driven by growth in France ($20.5M), Germany ($14.1M), and other international markets ($21.7M). This was partially offset by a $6.2 million decrease in U.S. revenue due to a reduction in one-time benefits from prior period claims.
- Cost of Revenues: Increased by 22% to $166.9 million. Drivers included a 9% increase in Optune Gio active patients, higher array costs ($3.4M), NSCLC launch costs ($3.6M), higher tariffs ($5.2M), and increased sales to Zai Lab ($3.1M). A $3.2 million inventory obsolescence provision for Optune Lua arrays was also recorded.
- Operating Expenses: Total operating expenses remained relatively flat (+1%). Research and Development (R&D) increased by 7% due to product development and clinical trial ramp-ups (LUNAR-2, KEYNOTE D58). General and Administrative (G&A) expenses decreased by 6%, primarily due to a $28.8 million reduction in share-based compensation compared to 2024.
- Debt Structure: The company fully repaid its $575 million convertible notes in November 2025. It simultaneously drew down Tranche B ($100M) of its new senior secured credit facility, bringing total outstanding debt to $200 million. The company is no longer eligible to draw Tranche C or D loans.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- Optune Mya: A PMA application for brain metastases from NSCLC (based on the METIS trial) was submitted in December 2025 and is under substantive FDA review.
- Optune Pax: FDA approval for pancreatic cancer was received in February 2026 (subsequent event). The company is pursuing international approvals.
- Clinical Trials: Topline data for the TRIDENT trial (GBM) is anticipated in Q2 2026. The LUNAR-2 trial (NSCLC) and PANOVA-4 trial (pancreatic cancer) are ongoing.
Management Commentary: Management expects R&D, sales, and marketing expenses to continue to increase over the next several years, potentially outpacing gross profit. They believe current cash and investments are sufficient for operations for at least the next 12 months but may need to raise additional capital in the future.
Risks and Contingencies:
- Reimbursement: The company faces uncertainty regarding reimbursement for Optune Lua (NSCLC/MPM) and Optune Pax in various markets. In the U.S., Medicare coverage for Optune Gio is established, but coverage for new indications is pending.
- Supply Chain: The company relies on single-source suppliers for some components, with some located in Israel. Conflict in Israel poses a risk to operations, though the company has increased safety stocks.
- Tariffs: Changing global tariff environments could impact gross margins, though management currently anticipates no material short-term impact.
- Patent Expirations: Several early patents covering TTFields technology began expiring in 2021, with more expiring between 2025 and 2041.
Key Facts for Investor Verification
- Active Patient Count: Verify the total active patient count of 4,620 (4,464 Optune Gio, 156 Optune Lua) as of December 31, 2025, and the growth rate in key markets (U.S., Germany, France, Japan).
- Reimbursement Status: Confirm the status of national reimbursement approvals for Optune Lua (NSCLC/MPM) and Optune Pax in major international markets, as these are critical for future revenue scaling.
- Debt Covenants: Review the financial covenants of the Senior Secured Credit Facility, specifically the requirement to maintain trailing four quarters of net revenue of at least $500 million if Tranche C or D were funded (currently not applicable as those tranches were not drawn).
- Inventory Obsolescence: Investigate the $3.2 million inventory write-down for Optune Lua arrays and the potential for future write-offs as the company transitions to new array designs.
- Share-Based Compensation: Note the significant decrease in share-based compensation expense in 2025 ($104.8M vs $160.0M in 2024) and assess the sustainability of this reduction in future periods.